{"id":3997,"date":"2025-03-31T18:11:55","date_gmt":"2025-03-31T18:11:55","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/fludarabine-phosphate-txt\/"},"modified":"2025-03-31T18:11:55","modified_gmt":"2025-03-31T18:11:55","slug":"fludarabine-phosphate-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/fludarabine-phosphate-txt\/","title":{"rendered":"Fludarabine phosphate.txt"},"content":{"rendered":"

Fludarabine phosphate <\/h1>\n

CLINICAL USE <\/H3>
\nB-cell chronic lymphocytic leukaemia

DOSE IN NORMAL RENAL FUNCTION <\/H3>IV: 25 mg\/m2 daily for 5 days, repeated every 28 daysOral: 40 mg\/m2 for 5 days every 28 days

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :365.2<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :19\u201329<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 40\u201360<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.8\u20134<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :20\/24

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>30\u201370 50\u201375% of normal dose10\u201330 50\u201375% of normal dose. Use with care
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 50% of normal dose. Use with care

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR=10\u201330 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosisCytotoxics: increased pulmonary toxicity with pentostatin (unacceptably high incidence of fatalities); increases intracellular concentration of cytarabine

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>Reconstitute each vial with 2 mL of water to give a concentration of 25 mg\/mL

    Route <\/H4>IV, oral

    Rate of Administration <\/H4>Infusion should be administered over 30 minutes

    Comments<\/H4>IV bolus in 10 mL of sodium chloride 0.9%

    IV infusion <\/H4> in 100 mL of sodium chloride 0.9%

    OTHER INFORMATION <\/H4>Rapidly dephosphorylated in plasma to (2-F-9-\u00df-D-arabinofuranosyladenine) 2-F-ara-ATP, which is necessary for cellular uptakeApproximately 60% of an administered dose is excreted in the urine within 24 hrsAdminister up to achievement of clinical response (usually 6 cycles) then discontinuePatients with renal failure (GFR=17\u2013 41 mL\/min\/m2) receiving 20% of dose had a similar AUC as patients with normal renal function receiving the full doseFludarabine phosphate.
    \n","protected":false},"excerpt":{"rendered":"

    Fludarabine phosphate CLINICAL USE B-cell chronic lymphocytic leukaemia DOSE IN<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3997","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3997"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3997\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}